Lilly, Boehringer win EU nod for Jardiance combo med; J&J sells Cordis unit to Cardinal for $2B;

@FiercePharma: ICYMI: As Bayer preps for its slim-down, a restructuring looms--but jobs are safe, CEO says. Article | Follow @FiercePharma

@CarlyHFierce: ICYMI: Top Medicare prescribers get top payments from drugmakers: Modern Healthcare. Report | Follow @CarlyHFierce

> Eli Lilly ($LLY) and Boehringer Ingelheim won European approval for their combination diabetes pill Synjardy, which comprises the SGLT2 med Jardiance (empagliflozin) with the standard treatment metformin. Release

> Johnson & Johnson ($JNJ) agreed to sell its Cordis cardiovascular device unit to Cardinal Health ($CAH) in a $2 billion deal. Release

> Roche ($RHHBY) licensed its anemia therapy Mircera to Galenica, which will market the product in the U.S. and Puerto Rico. Report

> AMAG Pharmaceuticals ($AMAG) fell short in its FDA application for a one-dose vial of its preterm labor med Makena; the agency wants more information about procedures at its contract manufacturer. Release

> Bayer Healthcare's Indonesia unit is beefing up its warehousing and manufacturing in hopes of exporting to at least 50 countries within three years. Report

Medical Device News

@FierceMedDev: Roche's Ventana teams up with Halozyme for pancreatic cancer companion Dx. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Pacira's liposomal-encased bupivacaine gets positive reviews at breast cancer conference. FierceDrugDelivery report | Follow @VarunSaxena2

@EmilyWFierce: $SQNM is consolidating its labs. Release | Follow @EmilyWFierce

> Freedom Meditech, maker of diabetes eye scanner, raises $4.8M in Series C round. Article

> WSJ: J&J faces FBI probe over power morcellator devices. Report

Biotech News

@FierceBiotech: The White House draws the line against CRISPR/Cas9-designed embryos. More from FierceBiotechResearch | Follow @FierceBiotech

@JohnCFierce: Seres ($MCRB), joins $ADAP, $ADRO, $CDTX, $JUNO, Molecular Partners and $ONCE among the 2014 Fierce 15 biotechs to go for an IPO. | Follow @JohnCFierce

> Wall Street's open for biotech business, and Europe is taking notice. Item

> Booming Gilead is opening new labs, planning fresh hires in R&D blitz. Report

> Atlas' Padlock scoops up some GlaxoSmithKline assets in autoimmunity. Article

> A well-connected Pronutria revs up amino acid research with $39M C round. Story

Vaccines News

> World Health Assembly passes resolution on vaccine pricing, transparency. Item

> Serum Institute, Cipla partner to market flu vaccine in India. More

> Abivax seeks cash to bring Cuban-discovered HepB vaccine to the world. Story

> Hold the offer: Bavarian Nordic declares it's not for sale. Article

> Regeneus gets green light to move personalized cancer vaccine into PhI. Report

CRO News

> Parexel rejigs its randomization tech with an eye on speed. Item

> BioClinica partners up for risk-based management. More

> Ergomed snags a postmarketing firm with its eye on pharmacovigilance. Article

> EMA still wants 700 GVK-related drugs off the market. Story

> Quintiles homes in on Asian biotech with its latest offering. Report

Pharma Manufacturing News

> Bayer set to spend $3.4M this year to expand its Indonesian operations. Story

> Report: Claris Lifesciences injectables sale may hit roadblock by FDA Form 483. Item

> Aurobindo Pharma submits abbreviated application to FDA for HIV drug production. News

> Gerresheimer Glass to close NJ pharmaceutical bottle plant this summer. Article

> Gilead Sciences plans $100M expansion of Edmonton plant. Report

Pharma Asia News

> Singapore clinical hub to work with Visterra on dengue candidate. More

> TPP negotiators said to be zeroing in on clearing IP snags. Story

> Japan's cabinet tells health minister to dig deeper on costs. Article

> China to charge $102K for drug, device registration in first hike in two years. Item

> Russia makes it easier to skirt imported drug sale norms. Report

And Finally... Pandora's ($P) chief musicologist is working with Memorial Sloan Kettering Cancer Center on music therapy specifically for cancer patients. Report

Suggested Articles

China's role as a major producer of global API has come under scrutiny, but so far global tensions haven't affected supply, the FDA said.

Reblozyl, a key drug in Bristol Myers Squibb's Celgene merger, has won a key FDA nod to treat patients with myelodysplastic syndromes.

Wealthy individuals typically don't set out to waste billions of dollars, but amid the COVID-19 pandemic, that’s exactly what Bill Gates plans to do.